Harrow’s Second Quarter 2026: Growth, Acquisitions, and the Quiet Power of a Broad Ophthalmic Portfolio

Overview: Growth in the Rearview, Momentum Up Front

The Nashville-based Harrow reported its second quarter for 2026 ended June 30, 2026, with a blend of robust topline growth, a slate of product momentum, and an explicit path to higher annual revenue. The company posted quarterly revenue of $70.7 million, a sequential rise of 60% and a year-over-year gain of 11%. While the press release foregrounds revenue and cash flow metrics, investors will also be watching how this translates to earnings per share (EPS) and earnings surprise vs. previous expectations, given the absence of a GAAP EPS figure in the release and the emphasis on Adjusted EBITDA as the near-term profitability proxy.

Key Financial Highlights

• Quarterly revenue: $70.7 million — up 60% sequentially and 11% year over year.
• Full-year 2026 guidance (revenue): $350 million to $365 million; Adjusted EBITDA guidance: $80 million to $100 million.
• Product and segment momentum:
  • VEVYE: $29.4 million in quarterly revenue, up ~40% sequentially and ~58% YoY.
  • IHEEZO: $15.6 million in quarterly revenue, record quarterly unit demand up 44% sequentially and 34% YoY.
  • TRIESENCE: record quarterly unit demand, up 39% sequentially and 162% YoY.
• Operational note: A top-three national commercial pharmacy benefit manager (PBM) coverage win for VEVYE is effective August 1, 2026.
• Acquisition activity: TYRVAYA acquisition announced, expected to close in the second half of 2026.
• Balance sheet: Cash and cash equivalents of $83.9 million as of June 30, 2026.
• Market context: IHEEZO benefited from strong demand despite the loss of pass-through reimbursement, underscoring resilience in the portfolio even as reimbursement dynamics evolve.

Portfolio Highlights: A Diversified Suite with Cross-Sell Potential

The quarterly performance underscores Harrow’s multi-product strategy across ophthalmic disease management. VEVYE, a sizeable revenue contributor, benefited from continued prescriber and market-share gains, with a major coverage win in place for August. IHEEZO achieved its strongest quarter on record for unit demand, even as reimbursement headwinds persisted for pass-through arrangements. TRIESENCE likewise delivered a strong demand trajectory, signaling continued physician uptake and patient adoption. The company frames these results as building blocks for the 2026 and 2027 revenue objectives, with TYRVAYA’s pending close likely to broaden the portfolio and potentially amplify cross-selling across franchises.

Acquisition & Financial Position: TYRVAYA Comes Into View

The TYRVAYA acquisition, announced during the quarter and slated to close in H2 2026, is a meaningful strategic add, reinforcing Harrow’s growth platform in the ophthalmic space. Management highlighted the steps taken in H1 2026 to expand demand, strengthen pricing, and broaden the commercial footprint — all actions that could help convert demand into accelerating revenue growth and profitability in the second half of the year. On the liquidity side, Harrow ended June with approximately $84 million in cash, providing a firm cushion as it pursues inorganic opportunities and integrates TYRVAYA upon closing.

From the CEO: A Roadmap That Matches the Market’s Pace

“We spent the first half of 2026 building demand and positioning the business to achieve our 2026 and 2027 financial objectives. The second half of 2026 is about converting that demand into accelerating revenue growth and profitability,” said Mark L. Baum, Chairman and CEO of Harrow. “Over the past six months, we expanded our commercial organization, strengthened our portfolio, improved pricing across key products, launched BYOOVIZ, advanced multiple clinical programs, and announced the acquisition of TYRVAYA. VEVYE delivered record quarterly revenue while improving its underlying economics, and momentum continues to build, supported by our recent coverage win that went into effect August 1. IHEEZO achieved the strongest commercial quarter in its history despite the loss of pass-through reimbursement, and TRIESENCE continued to generate exceptional demand growth – reinforcing our conviction that physician demand continues to strengthen across our portfolio.”

What This Could Portend for Harrow and Its Sector Peers

The quarter paints a picture of a growth engine that thrives on a mix of high-demand products, payer wins, and selective M&A. The VEVYE coverage expansion with a major PBM could catalyze durable revenue gains if the formulary positioning persists and utilization follows. IHEEZO’s resilience in the face of reimbursement changes suggests Harrow’s portfolio has built-in demand elasticity, though the erosion of pass-through reimbursement remains a variable that could impact margins and the EPS narrative if not offset by volume and pricing gains.

TYRVAYA’s anticipated close adds a layer of strategic optionality. If the integration behaves as advertised, cross-sell opportunities among VEVYE, IHEEZO, and TRIESENCE could improve lifecycle value and push the revenue forecast higher, while pushing the EBITDA needle in a direction that would make EPS accretive as the company leverages its combined scale. The absence of a disclosed EPS figure leaves EPS consensus as a forward-looking question for analysts, making the near-term stock reaction more about margins, synergy realization, and the timing of TYRVAYA’s contribution than a one-quarter surprise in earnings per share.

For sector peers, Harrow’s experience illustrates a broader investor preference for diversified ophthalmic platforms that can weather reimbursement shifts and still grow top line through new products and payer wins. The market’s temperature for acquisitions, cash density, and cadence of product launches will likely shape how other players defend or extend their own franchises in this space.

Final Take: A Portfolio-Driven Path Forward

Harrow’s Q2 2026 results emphasize growth through a balanced portfolio, strategic partnerships, and a clear line of sight to higher annual revenue in 2026 and 2027. While the press release centers on revenue, segment demand, and acquisitions, investors will be weighing how soon EPS translates from EBITDA-driven guidance and how TYRVAYA’s integration modulates gross margins and operating leverage. If Harrow can convert demand into sustained profitability while expanding its addressable market, the company may become a steadier component in ophthalmic-healthcare equities than the near-term chatter about big-ticket deals might imply.